China Pharma Holdings, Inc.

CPHI • Drug Manufacturers - Specialty & Generic

$0.72

▲ +0.04 (+5.73%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$29.35M

Crecimiento

23.1%

Flujo de caja

1/5

Tendencia

Volatile

Evidencia

Flujo de caja libre positivo · 0Nivel de deuda manejable · 0.17Liquidez débil · 0.32Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:12 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.72

Change5.73%

Shares Out40.52M

Market Cap$29.35M

Enterprise Value$-156.48B

52W Range0.38 - 19.19

Beta1.07

P/E-0.00

P/S0.00

P/B0.00

P/FCF-0.00

EV/Sales-0.17

Price$0.72

Change5.73%

Shares Out40.52M

Market Cap$29.35M

Enterprise Value$-156.48B

52W Range0.38 - 19.19

Beta1.07

P/E-0.00

P/S0.00

P/B0.00

P/FCF-0.00

EV/Sales-0.17

EV/EBITDA0.11

EV/FCF1.78

Dividend Yield0.00%

Gross Margin-3.18%

Oper. Margin-74.53%

Profit Margin-76.91%

Debt/Eq0.17

Current Ratio0.32

Quick Ratio0.10

Revenue 5Y23.09%

Volume737.80K

Avg Volume4.44M

EPS Surprise-0.40

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

39/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

69/100

Por qué este puntaje▼

Flujo de caja libre positivo · 0Nivel de deuda manejable · 0.17Liquidez débil · 0.32Tendencia de crecimiento negativaRentabilidad débil

Analyst view

No analyst data available now.

Resumen de la compañía

IPO: 4/17/2002

Industria: Drug Manufacturers - Specialty & Generic

P/B i: 0.00

Deuda / Patrimonio i: 0.17

Margen operativo: -74.53%

Margen neto: -76.91%

ROE i: -

ROIC: -

Salud financiera

Puntaje8 / 20

Deuda / Patrimonio: 0.17

Ratio corriente: 0.32

Ratio rápido: 0.10

Estado: Moderate

Advertencias

Weak Liquidity
Weak quick ratio

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 2 venta interna de alto volumens detectadas

Liu Tao (Chengdu)

Transacción: 12/28/2023

VENTA

Cambio

Precio

Not reported

Presentación

01/26/2024

Tipo

VENTA

Li Zhilin

Transacción: 09/29/2023

COMPRA

Cambio

+13,757,063

Precio

$0.14

Presentación

10/19/2023

Tipo

COMPRA

Deng Ke

Transacción: 12/30/2022

VENTA

Cambio

Precio

Not reported

Presentación

03/09/2023

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Liu Tao (Chengdu)	VENTA	0	Not reported	12/28/2023	01/26/2024
Li Zhilin	COMPRA	+13,757,063	$0.14	09/29/2023	10/19/2023
Deng Ke	VENTA	0	Not reported	12/30/2022	03/09/2023
Li Zhilin	COMPRA	+1,760,000	$0.67	09/09/2021	09/13/2021
Li Zhilin	COMPRA	+2,000,000	Not reported	12/23/2020	01/08/2021
WAUNG FRANK	COMPRA	+100,000	Not reported	04/28/2012	05/01/2012
WAUNG FRANK	VENTA	-25,000	$2.54	05/25/2011	05/01/2012
WAUNG FRANK	VENTA	-150,000	$3.47	04/28/2010	05/01/2012
WAUNG FRANK	VENTA	-10,000	$2.75	10/13/2009	05/01/2012
WAUNG FRANK	COMPRA	+25,000	$2.54	05/25/2011	05/27/2011
WAUNG FRANK	COMPRA	+25,000	Not reported	05/25/2011	05/27/2011
Li Zhilin	COMPRA	+25,000	$2.54	05/25/2011	05/27/2011
Li Zhilin	COMPRA	+50,000	Not reported	05/25/2011	05/27/2011
WAUNG FRANK	COMPRA	+6,863	Not reported	12/13/2010	03/02/2011
WAUNG FRANK	COMPRA	+4,052	$3.06	11/15/2010	11/19/2010
WAUNG FRANK	VENTA	-40,000	$2.75	11/15/2010	11/19/2010
WAUNG FRANK	COMPRA	+200,000	$3.47	04/28/2010	11/19/2010
Tsui Heung Mei	VENTA	-1,500,000	$3.00	02/09/2010	02/10/2010
DONG BAOWEN	VENTA	0	Not reported	02/01/2008	10/19/2009
BENNETT G MICHAEL	OTRO	0	Not reported	02/01/2008	10/16/2009

Sobre la compañía

China Pharma Holdings, Inc.

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.

Fuente - Link

Competidores

AMIX ENSC FLGC KALA OGEN RDHL SNGX SNOA TTNP XBIO

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Thermo Fisher Scientific Showcases New Solutions and Expanded Capabilities to Accelerate Drug Development at CPHI Milan 2026

MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability.

Business Wire

Lifecore Biomedical to Participate at CPHI Global Conference

CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference.

GlobeNewsWire

China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering

HAIKOU, China, July 23, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) (the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced the closing of its previously announced registered direct offering of 2,500,000 shares of the Company's common stock, par value $0.001 per share, at a purchase price of $2.00 per share. The gross proceeds from the offering are $5 million, before deducting placement agent fees and other offering expenses.

PRNewsWire

China Pharma Announces Pricing of $5 Million Registered Direct Offering

HAIKOU, China, July 22, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that the pricing of its registered direct offering of 2.5 million shares of its common stock ("Common Shares"), at a purchase price of $2 per share. The gross proceeds from the offering will be $5 million, before deducting placement agent fees and other offering expenses.

PRNewsWire

China Pharma Holdings, Inc. Comments on Unusual Market Activity

HAIKOU, China, July 21, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 21, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it issued this statement under Section 401(d) of the NYSE American Company Guide that it was not aware of any material corporate developments that would explain the recent market activity.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2011-11-11	1.2	0.8	-0.4
2011-08-11	1.1	1.2	0.1
2011-05-11	1.15	1.2	0.05
2011-03-03	1.57	1.5	-0.07
2010-11-11	1.27	1.3	0.03
2010-08-10	1.1	1.2	0.1
2010-05-11	1.1	1	-0.1
2010-03-05	1.35	1.2	-0.15
2009-11-11	1.2	1.7	0.5
2009-08-11	1	1	0
2009-05-15	1.3	0.9	-0.4
2009-03-17	1.1	1.3	0.2